AKBA Stock Analysis: Buy, Sell, or Hold?
AKBA - Akebia Therapeutics, Inc.
$1.16
-0.02 (-1.69%)
▼
5d:
-17.14%
30d:
-17.73%
90d:
-16.55%
WAIT
LOW Confidence
Analysis Updated: May 8, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Smart Money Accumulation
AKBA is down 14.5% this week, but smart money is accumulating calls. Top strike: $2 2026-07-17 with 2,143 OI. Call ratio: 71% View Scanner →
Strength: 9.4/10
Get Alerted When AKBA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
11 traders called AKBA this week
84% bullish • 3 bearish
84% bullish • 3 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: AKBA is down 17.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: AKBA is down 17.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: AKBA is currently trading at $1.16, which is considered oversold relative to its 30-day fair value range of $1.32 to $1.48. From a valuation perspective, the stock is trading at a discount (Forward PE: -7.2) compared to its historical average (12.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AKBA is in a downtrend. Immediate support is located at $1.12, while resistance sits at $1.54.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.40 (+279.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AKBA is in a downtrend. Immediate support is located at $1.12, while resistance sits at $1.54.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.40 (+279.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.32 -
$1.48
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
Protect Your Profits
Holding AKBA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 279.3% below Wall St target ($4.40)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Recommendation downgraded due to -17.1% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.32 -
$1.48
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.13
Resistance Level
$1.54
Current Trend
Downtrend
Technical data as of
May 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.25
Wall Street Target
$4.40
(+279.3%)
Revenue Growth (YoY)
23.9%
Profit Margin
-2.3%
PE vs Historical
-7.3 vs 12.4
CHEAP
Share & Embed Analysis
Last updated: May 11, 2026 7:08 AM ET
Data refreshes hourly during market hours. Next update: 8:08 AM
Data refreshes hourly during market hours. Next update: 8:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AKBA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
NEUTRAL
Recent Transactions
John P Butler
BUY
69270 shares
2026-03-04
Richard C Malabre
SELL
49524 shares
2026-02-02
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 66 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$102 | 65 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$136 | 52 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 54 HOLD |
Advanced AKBA Option Strategies
Professional options setups generated by AI based on today's AKBA price and gamma walls.
